📊 Global Voxzogo Market Outlook 2026–2030
Growth driven by rising rare disease investments, genetic research, and demand for disease-modifying therapies.
Key trends:
• Targeted genetic therapies
• Early intervention focus
• Personalized pediatric treatments
North America leads the market.
📥 Get free sample:
https://www.thebusinessresearchcompany.com/report/voxzogo-global-market-report
📊 Vpriv Market Outlook to 2030
Growth driven by rising healthcare spending, rare disease treatment access, and advancements in enzyme therapies.
Key trends:
• Personalized dosing strategies
• Recombinant enzyme tech
• Long-term disease management
North America leads the market.
📥 Get free sample:
https://www.thebusinessresearchcompany.com/report/vpriv-global-market-report
New POSTnote briefing on 'Diagnosis and treatment of
rare genetic diseases' (POSTnote 763, doi.org/10.58248/PN763 ) has been published, with contributions from the UOI's Dominic Wilkinson.
I’ll attend the #EuroNDD Workshop in Warsaw in April. Anyone around the Fediverse going there as well? —> let’s connect!
I’m looking forward to present our work at https://www.findme2care.de AND hear about all the other projects.
Also: I’ll be co-hosting an educational session and roundtable discussion titled „Building Patient Registries under the GDPR – The Good, the Bad and the Ugly“ —> there are a few seats left for conference attendees!
#humangenetics #genetics #RareDiseases #RareDisease #ERN #ERNIthaca #patientregistry
How Rare Disease Patients Are Rewriting The Rules Of Medicine
anwar_tbrc
BioSchweiz
Miriam Pipe
The-14
Verband Angiodysplasie Schweiz
Uehiro Oxford Institute
Christian Gebhard